Skip to main content
SpringerLink
Log in

Sekundäre Vaskulitiden und Vaskulitis „Mimics“

Secondary vasculitides and vasculitis mimics

  • Leitthema
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Sekundäre Vaskulitiden, d. h. Vaskulitiden mit einem eindeutigen zeitlichen und pathogenetischen Zusammenhang zu einem meist exogenen auslösenden Agens (mikrobielle Erreger, Medikamente, Drogen) oder einem Tumor stellen eine wichtige differenzialdiagnostische Herausforderung dar, da die Elimination des auslösenden Agens nicht selten mit einer Remission oder zumindest Besserung der Vaskulitis einhergeht. Sekundäre Vaskulitiden kommen auch in Assoziation mit Kollagenosen, einer rheumatoiden Arthritis oder einer Sarkoidose vor. Unter Vaskulitis „Mimics“ versteht man Krankheitsbilder, deren klinische Symptome denen primärer oder sekundärer systemischer Vaskulitiden ähneln, denen aber pathophysiologisch und/oder histologisch keine Vaskulitis zugrunde liegt.

Abstract

Secondary vasculitis is a form of vasculitis for which an underlying disease is known. Diseases associated with secondary vasculitis include infections, drug hypersensitivity, malignancy, rheumatoid arthritis, collagen vascular disease and sarcoidosis. Moreover, there are numerous conditions that can mimic vasculitis clinically, in laboratory testing, radiographically and in histopathology. It is evident that distinguishing primary vasculitis from secondary vasculitis and also vascular inflammation from non-vasculitic disorders (vasculitis mimics) has significant therapeutic implications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Märker-Hermann E, Peter HH (2012) Sekundäre Vaskulitiden. In: Peter HH, Pichler W, Müller-Ladner U (Hrsg) Klinische Immunologie. Urban und Fischer, Elsevier, München, S 415–428

  2. Mader R, Keystone EC (1992) Infections that cause vasculitis. Curr Opin Rheumatol 4(1):35–38

    PubMed  CAS  Google Scholar 

  3. Ramos-Casals M, Nardi N, Lagrutta M et al (2006) Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) 85(2):95–104

    Google Scholar 

  4. Sato H, Hattori M, Fujieda M et al (2000) High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves‘ disease treated with propylthiouracil. J Clin Endocrinol Metab 85(11):4270–4273

    Article  PubMed  CAS  Google Scholar 

  5. Slot MC, Links TP, Stegeman CA et al (2005) Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: a long-term followup study. Arthritis Rheum 53(1):108–113

    Article  PubMed  Google Scholar 

  6. Csernok E, Lamprecht P, Gross WL (2010) Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis. Curr Opin Rheumatol 22(1):43–48

    Article  PubMed  CAS  Google Scholar 

  7. Gao Y, Zhao MH (2009) Review article: drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton) 14(1):33–41

    Google Scholar 

  8. Bonaci-Nikolic B, Nikolic MM, Andrejevic S et al (2005) Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides. Arthritis Res Ther 7(5):R1072–1081

    Article  PubMed  CAS  Google Scholar 

  9. Noh JY, Asari T, Hamada N et al (2001) Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves‘ disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol (Oxf) 54(5):651–654

    Google Scholar 

  10. Beasley R, Bibby S, Weatherall M (2008) Leukotriene receptor antagonist therapy and Churg-Strauss syndrome: culprit or innocent bystander? Thorax 63(10):847–849

    Article  PubMed  Google Scholar 

  11. Nathani N, Little MA, Kunst H et al (2008) Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax 63(10):883–888

    Article  PubMed  CAS  Google Scholar 

  12. Gadola SD, Moins-Teisserenc HT, Trowsdale J et al (2000) TAP deficiency syndrome. Clin Exp Immunol 121(2):173–178

    Article  PubMed  CAS  Google Scholar 

  13. Simsek S, Vries XH de, Jol JA et al (2006) Sino-nasal bony and cartilaginous destruction associated with cocaine abuse, S. aureus and antineutrophil cytoplasmic antibodies. Neth J Med 64(7):248–251

    PubMed  CAS  Google Scholar 

  14. Schultz H, Schinke S, Weiss J et al (2003) BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections. Clin Exp Immunol 133(2):252–259

    Article  PubMed  CAS  Google Scholar 

  15. Gross RL, Brucker J, Bahce-Altuntas A et al (2011) A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine. Clin Rheumatol 30(10):1385–1392

    Article  PubMed  Google Scholar 

  16. Kronzon I, Saric M (2010) Cholesterol embolization syndrome. Circulation 122(6):631–641

    Article  PubMed  Google Scholar 

  17. Reinhold-Keller E, Mohr J, Christophers E et al (1992) Mesna side effects which imitate vasculitis. Clin Investig 70(8):698–704

    Article  PubMed  CAS  Google Scholar 

  18. Reinhold-Keller E, Schmitt WH, Gross WL (2001) Azathioprine toxicity mimicking a relapse of Wegener’s granulomatosis. Rheumatology (Oxford) 40(7):831–832

    Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt für sich und seinen Koautor an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Med Klinik III (Nephrologie, Hypertensiologie, Rheumatologie), Klinikum Offenbach GmbH, Offenbach, Deutschland

    K. de Groot

  2. Klinik Innere Medizin IV (Rheumatologie, klinische Immunologie, Nephrologie), HSK Dr. Horst Schmidt Kliniken GmbH, Ludwig Erhard Str. 100, 65199, Wiesbaden, Deutschland

    E. Märker-Hermann

Authors
  1. K. de Groot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Märker-Hermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Märker-Hermann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Groot, K., Märker-Hermann, E. Sekundäre Vaskulitiden und Vaskulitis „Mimics“. Z. Rheumatol. 71, 771–774 (2012). https://doi.org/10.1007/s00393-012-0986-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-012-0986-8

Schlüsselwörter

Keywords

Search

Navigation